🔥 What This Document Is

This is an 8-K filing, which is a report of major events that shareholders should know about. This specific filing includes a press release (Exhibit 99.1) detailing Fortress Biotech's full-year 2025 financial results and a rundown of major corporate events from the past year. Think of it as the company's annual highlight reel and report card.

🏢 What The Company Does

👉 In simple terms, Fortress Biotech is a biotech "builder and portfolio manager." They don't just focus on one drug. Instead, they acquire, fund, and develop a diverse portfolio of drug candidates and products across subsidiaries and partner companies. Their goal is to create value through product sales, owning equity in these entities, and earning royalties. They work in areas like oncology (cancer), dermatology (skin), and rare diseases.

💰 Financial Highlights

Let's break down the key numbers for the full year 2025:

Net Loss Per Share: The company reported a net loss of $(0.07) per share for 2025. This is a massive improvement from the $(2.69) per share loss in 2024.
Revenue: Total net revenue was $63.3 million, up from $57.7 million in 2024. Most of this ($61.2 million) came from their marketed dermatology product, Emrosi™.
Cash Position: As of December 31, 2025, they had $79.4 million in cash. This is up from $57.3 million a year ago, giving them more financial runway.
Expenses: Research & Development (R&D) spending dropped sharply to $11.9 million from $56.9 million in 2024, as fewer late-stage trials were in progress. Selling & administrative costs rose to $96.4 million.

👉 Why it matters: The much smaller loss per share and higher cash balance show improved financial health. The shift from heavy R&D spending to commercial revenue is a positive sign for their business model.

🚀 Key Moves & Monetization

Fortress executed several major deals to turn its pipeline into cash:

Sold a Priority Review Voucher (PRV) for $205 million: After its subsidiary Cyprium got FDA approval for the rare disease drug ZYCUBO®, they sold the valuable voucher that came with it. Fortress expects to receive at least $100 million of this after costs.
Sold Checkpoint Therapeutics to Sun Pharma: This deal generated ~$28 million upfront for Fortress and, more importantly, a 2.5% royalty on future sales of the cancer drug UNLOXCYT™. They could get up to $4.8 million more from a contingent payment.
Raised $205 Million for a Gout Drug: The subsidiary Crystalys raised a huge Series A round to advance the drug dotinurad into Phase 3 trials. Fortress's subsidiary gets a 3% royalty on future sales.

👉 Why it matters: These moves are the core of the Fortress model. They successfully advanced assets, got them approved or partnered, and then monetized them to fund the company and reward shareholders.

📦 Financial Position & Balance Sheet

Here’s what their financial snapshot looks like:

Total Assets: $185.5 million, up from $144.2 million in 2024.
Total Debt: They have $52.4 million in long-term notes payable. They recently used cash from the PRV sale to pay down debt, leaving $15.0 million outstanding.
Stockholders' Equity: It flipped from a small deficit to positive $62.2 million, largely due to gains from selling subsidiaries and improved earnings.

👉 Why it matters: The company's balance sheet is stronger, with more cash, less debt, and positive equity. This reduces financial risk.

🔮 What's Next

The company is focused on:

Commercializing recently approved drugs like ZYCUBO® and UNLOXCYT™ through partners.
Advancing clinical trials, notably the Phase 3 studies for dotinurad (gout) and the Triplex CMV vaccine.
Seeking a path forward for other pipeline drugs like ATX-04 for Pompe disease, with an FDA meeting planned for 2026.
Continuing its model of building value through its portfolio to create shareholder returns.

⚖️ The Big Picture

Strengths (👍):

Proven Monetization Model: Successfully turning assets into large cash payments ($205M PRV, Checkpoint sale).
Diverse Revenue Streams: Royalty streams from multiple partners (Sentynl, Sun Pharma, Crystalys) provide future income.
Stronger Financials: Improved cash position and a much narrower net loss.

Risks (⚠️):

Still Unprofitable: The company is not yet consistently profitable on a net-income basis.
Execution Risk: Success depends on its many subsidiaries and partners executing clinical trials and commercial launches.
Dependence on Partners: Its model relies on the performance and decisions of other companies.

🧠 The Analogy

Fortress Biotech is like a venture capital fund for biotech drugs. They identify promising science, provide the funding and expertise to de-risk it (through development), and then either "cash out" by selling the mature asset (like Checkpoint) or collect ongoing "dividends" in the form of royalties from the successful drugs. This year was a prime example of successful exits.

📇 Key Contacts & People

Jaclyn Jaffe - Fortress Biotech, Inc. | (781) 652-4500 | [email protected]
Tony Plohoros (Media) - 6 Degrees | (908) 591-2839 | [email protected]
Lindsay A. Rosenwald, M.D. - Chairman, President & CEO

🧩 Final Takeaway

Fortress Biotech delivered on its "build and monetize" strategy in 2025, turning approved drugs and pipeline assets into significant cash inflows. This de-risked the company, strengthened its balance sheet, and set the stage for future growth through ongoing royalties and clinical advances. The core test now is whether it can sustain this model and achieve consistent profitability.

Fortress Biotech, Inc. — 8-K Filing